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Abstract
Background: The aim of this study was to investigate the incidence and prognostic value of disseminated tumor
cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to
lymph node involvement, determined by sentinel lymph node (SLN) biopsy analysis, and to prognostic factors of
interest.
Methods: 104 patients with operable (T < 3 cm) breast cancer and clinically- and sonographically-negative axillary
lymph nodes were scheduled for SLN biopsy. Bone marrow aspirates were collected before the start of surgery
from both iliac crests, and mononuclear cell layers were separated by density centrifugation (Lymphoprep). Slide
preparations were then examined for the presence of disseminated tumor cells by immunocytochemistry with
anti-cytokeratin antibodies (A45-B/B3). Lymphoscintigraphy was performed 2 hours after intratumor administration
of 2 mCi (74 MBq) of 99mTc colloidal albumin. The SLN was evaluated for the presence of tumor cells by
hematoxylin-eosin staining and, when negative, by immunocytochemistry using anti-cytokeratin antibody (CAM
5.2). Survival analyses and comparative analyses were performed on the results of bone marrow determinations,
SLN biopsy, and known prognostic factors, including breast cancer subtypes according to the simplified
classification based on ER, PR and HER2.
Results: Lymph node and hematogenous dissemination occur in one-third of patients with early-stage breast
cancer, although not necessarily simultaneously. In our study, disseminated tumor cells were identified in 22% of
bone marrow aspirates, whereas 28% of patients had axillary lymph node involvement. Simultaneous lymph node
and bone marrow involvement was found in only 5 patients (nonsignificant). In the survival study (60 months), a
higher, although nonsignificant rate of disease-related events (13%) was seen in patients with disseminated tumor
cells in bone marrow, and a significant association of events was documented with the known, more aggressive
tumor subtypes: triple negative receptor status (21%) and positive ERBB2 status (29%).
Conclusions: Tumor cell detection in bone marrow can be considered a valid prognostic parameter in patients
with early disease. However, the classic prognostic factors remain highly relevant, and the newer breast cancer
subtypes are also useful for this purpose.
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Breast cancer is a leading cause of death in middle-aged
women in developed countries. The incidence of this
condition appears to show an upward trend, and it is
now one of the priority issues in community health. In
Spain, breast cancer is the most common malignancy in
women and the leading cause of cancer deaths. The inci-
dence rate has risen from 54.8 cases per 100,000 woman-
years in 1980-1984 to 83.1 in 2000-2004 [1]. Mortality
has shown a downward trend from 1992 to 2005, but it
still reaches rates of 27.4 per 100,000 women [2].
Early detection of breast cancer is the basis of effective
treatment. Recognized prognostic indicators, such as
tumor size, grade and histological type, and steroid hor-
mone receptor status are defining characteristics of
tumor proliferation and the degree of differentiation;
hence, these parameters provide indirect information on
the capability of the tumor to metastasize.
The axillary lymph node status, determined by senti-
nel lymph node (SLN) biopsy or complete axillary node
dissection, is currently the most widely accepted direct
indicator of breast cancer spread. Lymph node involve-
ment is, therefore, a prognostic indicator of the risk of
systemic disease. Survival curves according to lymph
node involvement are classic descriptors of the natural
history of breast cancer [3].
In contrast, consolidated data indicate that approxi-
mately 10% to 20% of patients have metastatic disease at
the time of surgery in the absence of lymph node invol-
vement [4]. Moreover, it has been reported that up to
30% of patients in whom lymph nodes are not affected
experience recurrence within 10 years after surgery [5].
Early hematogenous spread has been proposed as a
prognostic indicator that would explain the errors in
prognoses established in the initial stages of the disease.
Detection of disseminated tumor cells (DTC) in bone
marrow is not uncommon, but there are substantial dif-
ferences (2%-60%) in the reported rates. The incidence
seems to be lower and more consistent in the early
stages of disease: 13.3% at diagnosis [6], 31% in patients
with stage I-II [7], and 19% in T0-2 tumors [8]. The
independent prognostic value of DTC remains when it
is assessed together with lymph node involvement [9]
and in multivariate analysis with clinical parameters of
survival in patients with stage I, II, and III disease [8].
Microarray analysis has identified breast cancer sub-
types with differing gene expression profiles [10,11].
These subtypes have been correlated with clinical out-
come, and the impact of subtype on response to neoad-
juvant chemotherapy has been evaluated [12]. Certain
easily assessable markers can be used to approximate
the breast cancer subtype. Specifically, by determining
the estrogen receptor (ER), progesterone receptor (PR),
and HER2 status of a tumor, breast subtype can be
approximated as follows: luminal A (ER+ or PR+ and
HER2-), luminal B (ER+ or PR+ and HER2+), HER2
+/ER- (ER- and PR- and HER2+), and triple-negative
(ER- and PR- and HER2-) [13,14].
The aim of this study was to determine the incidence
and prognostic value of DTC present in bone marrow of
patients with early-stage breast cancer, and the relation-
ship of this factor with lymph node involvement
assessed by SLN biopsy and other clinical parameters of
prognostic interest, including breast cancer subtypes
based on ER, PR, and HER2 status.
Methods
This is a prospective, observational study, in which
breast carcinoma patients were evaluated for the pre-
s e n c eo fD T Ci nb o n em a r r o w .T h es t u d yw a sc o n -
ducted at University Hospital Germans Trias i Pujol in
Badalona (Spain). The recruitment period was between
2002 and 2004, and last follow-up was in 2009.
The study population included all consecutive women
diagnosed with breast carcinoma in an early stage
(tumor size < 3 cm, clinically- and sonographically-nega-
tive axillary nodes, and no known metastasis) who were
referred for surgical treatment (mastectomy or lumpect-
omy, and SLN biopsy) during the recruitment period.
The exclusion criteria were a history of surgery or axil-
lary radiation therapy, neoadjuvant chemotherapy, preg-
nancy or lactation, and patients with clinical or personal
characteristics that would hinder monitoring. Patients
signed an informed consent form for participation in
the study. The study was approved by the Ethics and
Clinical Research Committee of our hospital and was
designed in compliance with the Helsinki Declaration.
Sentinel Node Detection and Biopsy
Lymphoscintigraphy was performed 2 hours after intra-
tumor administration of 2 mCi (74 MBq) of 99mTc
colloidal albumin. Tracer administration was guided by
sonography or mammography; hence, the radioguided
occult lesion localization (ROLL) technique was also
available. After intraoperative SLN detection and biopsy,
the specimen was evaluated for the presence of tumor
cells both intraoperatively with a fast variation of May
Grünwald-Giemsa staining, and definitively by multilevel
sectioning and hematoxylin-eosin staining. When tests
were negative, immunocytochemistry using an anticyto-
keratin antibody (CAM 5.2) was performed (Figure 1).
Immunocytochemical Determination of Disseminated
Tumor Cells in Bone Marrow
The method used for the immunocytochemical determi-
nations was based on the standards set by the European
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International Society of Hematotherapy and Graft Engi-
neering (ISHAGE) [15], with an adaptation to our
laboratory.
Prior to the surgical procedure and while the patient
was anesthetized, bone marrow aspirates were collected
from both anterior iliac crests to obtain a 10-mL speci-
men. The core sample was immediately processed by
density centrifugation using Lymphoprep (Nycomed,
Oslo, Norway). Centrifugation results in redistribution of
the components according to density, so that mononuc-
lear cells and breast tumor cells are presented in an easily
separated layer. Cells were recovered, counted, and pre-
pared for immunocytochemical staining. Marrow aspirate
samples were analyzed quantitatively using the alkaline
phosphatase-alkaline antiphosphatase technique, seeking
epithelial cells with cytokeratin expression. The monoclo-
nal antibody, antiCK A45-B/B3 (Micromet, Munich,
Germany), which is a combination of antibodies directed
against cytokeratin 8, 18, and 19, was used in a total of
2×1 0
6 cells (Figure 2).
Before applying the technique in clinical practice, it
was used to evaluate bone marrow from 10 patients
without cancer to validate its specificity. In addition, the
technique was calibrated using MCF-7 breast cancer
cells at different dilutions spiked into mononuclear cells
from patients without breast cancer.
During the clinical phase, all breast cancer specimens
were systematically examined in parallel with controls
consisting of slides stained with isotype-matched immu-
noglobulin. Morphological analysis with light micro-
scopy was used in all specimens to rule out nonspecific
staining in nonmetastatic cells. Bone marrow specimens
and sentinel nodes were examined by independent
observers.
Patient Follow-Up
Follow-up was carried out according to the standard
hospital protocol established by the breast pathology
unit. All patients received adjuvant chemotherapy and/
or hormonal therapy according the institutional and
international guidelines [16], starting no later than 6
weeks after surgery. In addition, all patients treated with
conservative breast surgery received external radiother-
apy. Subsequently, clinical follow-up visits were sched-
uled every 3 months during the first 2 years and every 6
months up to 5 years. These visits included a physical
examination, in which particular attention was placed
on lymph node evaluation and identification of metasta-
sis. Tumor markers were assessed every 6 months.
Chest radiography and mammography were performed
once a year. Bone scintigraphy, abdominal ultrasound
study, or computed tomography (CT) scanning was
done in cases of suspected relapse.
Study Variables and Data Analysis
The study variables were patient age, tumor-related
characteristics including size, location, radiological pre-
sentation, grade, lymphovascular invasion and histologi-
cal type, and hormone receptor (HR) status, including
estrogen, progesterone, and HER-2 overexpression.
Based on ER, PR, and HER2 status, tumors were classi-
fied into three subtypes: ERBB2+ (HR - and Erb-B2
receptor +), triple negative (HR and HER-2-negative)
and luminal (combination of positive estrogen receptor
with any progesterone result or Erb-B2 status. SLN sur-
gical and biopsy results, and DTC findings from bone
marrow aspirates were also recorded. The follow-up
variables included type and duration of treatment,
follow-up period, and overall and disease-free survival.
A descriptive analysis was performed of all variables.
Qualitative variables were described using frequency
Figure 2 Isolated tumor cell in bone marrow.
Figure 1 Sentinel node micrometastasis.
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ables as the mean and standard deviation (SD).
Associations between variables of interest were ana-
lyzed. The chi-square test was used to compare qualita-
tive variables. Comparisons between quantitative and
qualitative variables were performed with the Student t
test (dichotomous variables) or ANOVA (variables with
more than two categories), taking into account the pos-
sibility of using nonparametric tests.
For hypothesis testing, a two-tailed P value of 0.05 and
power of 80% were used. The data analysis was per-
formed with SPSS for Windows (version 15.0).
Results
A total of 104 patients with mean age of 55.6 years
(30-87) were studied. Mean tumor size was 1.87 cm
(range, 0.5-4 cm).
Lymphoscintigraphy was performed 2 to 18 hours
after tracer injection. There was no tracer migration to
the axillary region in 6 cases, making subsequent lym-
phadenectomy necessary. One node was detected in 59
patients, 2 nodes in 31 patients, 3 nodes in 7 patients,
and 4 nodes in 1 patient. Internal mammary drainage
occurred in 20 patients.
Axillary SLN biopsy was positive in 27 of 98 cases
(28%) (Table 1). Micrometastasis was found in 17
patients (63%), but 4 of them did not undergo lympha-
denectomy because they entered in the AATRM trial, a
multicenter clinical trial conducted in our center [17].
A second node was found to be affected in 4 of the 13
lymphadenectomies carried out (31%), in one case with
micrometastasis. Of the 10 patients who underwent
lymphadenectomy after detection of SLN macrometas-
tasis, nodes other than the SLN were positive in 4
patients. There were no cases of internal mammary
SLN involvement. Lastly, in 2 of the 6 patients with no
tracer migration, lymphadenectomies were positive,
yielding a total of 29 patients with lymph node
involvement.
Iliac crest bone marrow aspirates were successfully
collected in all patients, with bilateral extraction in 85%
of them. The mean volume obtained was 10 mL (range,
4-15 mL). One or two isolated tumor cells were found
in 23 patients (22%).
Of the 23 patients with positive bone marrow aspirates,
lymph node involvement was negative in 18 patients and
was positive in 5 patients, 1 of whom showed microme-
tastasis. Thus, only 5 patients (4.8%) tested positive to
both lymph node and bone marrow involvement, with no
overall correlation between the two routes of metastatic
spread (chi-square = 0.232; P = 0.63) (Table 2).
The results of the evaluation of clinical and pathologi-
cal characteristics are shown in Table 3. Lymph node
spread was related to younger age (P < 0.05), whereas
larger tumor size, infiltrating ductal histological pattern,
high grade, and lymphovascular invasion were relevant,
but non-significant, factors. Hematogenous spread was
related to older age (P < 0.05), radiologic presentation
a san o d u l e( P < 0.05), and internal/central mammary
localization (P < 0.05), whereas high grade, and positive
estrogen and progestogen receptor status were present
as relevant, but not significantly related.
According to the established hospital protocols,
patients received adjuvant chemotherapy (71%) and hor-
monal therapy (29%); within this total, 12% were given a
sequential combination of both treatments. Considering
that patients were included before the publication of the
results of adjuvant trastuzumab, none of the patients
included received this drug as adjuvant therapy [18-20].
Patients who underwent conservative surgical treatment
(80%) received radiotherapy. Follow-up reached 60
months in all patients (maximum 90 months). The
patients’ clinical course and the relationship between
clinical course and lymphatic and hematogenous invol-
vement are shown in Table 4. Cancer-related deaths
occurred in 4 patients, and 4 others presented disease
relapse, consisting of local progression (2 patients) or
distant disease recurrence (2 patients). None of these
patients were among those included in the AATRM
trial. Neither lymphatic involvement (RR = 1.3; 95%
CI = 0.12-13.8) nor hematogenous involvement (RR =
1.8; 95% CI = 0.17-18.9) reached a significant overall risk.
Analysis of the relationships between the different
breast cancer subtypes and disease-free survival showed a
Table 1 Results of sentinel lymph node biopsy
Patients Positive
SN
Lymphadenectomy Positive
node other
than SN
No axillary
migration
66 2
Axillary
drainage
98 17
micromets
13 4
10
macromets
10 4
Internal
mammary
drainage
20 0
Abbreviations: macromets, macrometastasis; micromets, micrometastasis; SN,
sentinel node
Table 2 Results for lymph node and bone marrow
involvement
BMi+ BMi-
LNi+ 5 (4.8%) 24 (23%)
LNi- 18 (17.3%) 57 (54.8%) ns
Abbreviations: LNi, lymph node involvement; BMi, bone marrow involvement;
ns, nonsignificant
Solá et al. BMC Cancer 2011, 11:252
http://www.biomedcentral.com/1471-2407/11/252
Page 4 of 8higher incidence of HER-2-positive tumors and HR-nega-
tive plus HER-2-negative tumors in patients who relapsed
or died due to the disease (p < 0.01); whereas no relation-
ship was found between these subtypes and the presence
of DTC in bone marrow (Table 5).
Discussion
The main objective of the present study was to estimate
the incidence of disseminated tumor cells in bone mar-
row as a criterion for assessing hematogenous metastatic
spread in patients with breast carcinoma. In addition,
the correlations between this feature and axillary lymph
node involvement were determined in patients who
underwent sentinel node biopsy. The study, which was
conducted between 2002 and 2009, assessed disease-free
and overall survival.
The immunocytochemistry results obtained in bone
marrow using a combination of antibodies directed
against cytokeratins 8, 18, and 19, indicate a 22% inci-
dence of DTC, which is in the reported range (12.5%-
28%) documented in the early stages of breast carci-
noma[21,22].
Although a higher frequency of DTC was found in the
subgroup of patients who experienced a relapse (13% vs.
6 % ,n s )o rd i e do fc a n c e r( 9 %v s .3 % ,n s ) ,t h es t a t i s t i c a l
study did not validate the prognostic value of the
results. This is likely because a low rate of events (8 of
104 patients) occurred over the follow-up period, as
would be expected in patients surgically treated at an
early stage of the disease and receiving systemic che-
motherapy or hormone therapy, as well as additional
radiotherapy in those with conservative surgery.
Other authors have reported results that are more
decisive. In a review published in 2005 by Braun and
Table 3 Comparative analysis of clinical characteristics and prognostic factors in patients with lymph node or bone
marrow involvement
LNi- (n = 75) LNi+ (n = 29) BMi- (n = 81) BMi+ (n = 23)
Age, y 57.4 50.8 P = 0.003 53.6 62.4 p = 0.007
Tumor size, cm 1.88 2.16 ns 1.97 1.88 ns
Location
External quadrants 68% 65% ns 73% 48%
Internal quadrants 32% 35% 27% 52% p = 0.045
Radiological presentation
Nodule 71% 76% ns 67% 91%
Microcalcification or distortion 29% 24% 33% 9% p = 0.04
Histological type
Ductal infiltration 85% 90% ns 87% 87%
No ductal infiltration 15% 10% 13% 13% ns
Tumor grade
I 27% 12% ns 23% 22%
II-III 73% 88% 77% 78% ns
Lymphovascular invasion 11% 21% ns 13% 13% ns
Positive estrogen receptor status 70% 70% ns 69% 76% ns
Positive progesterone receptor status 59% 63% ns 58% 67% ns
Positive Erb-B2 receptor status 33% 19% ns 28% 30% ns
Abbreviations: LNi, lymph node involvement; BMi, bone marrow involvement; ns, nonsignificant
Table 4 Clinical outcome
LNi- LNi+ BMi- BMi+
Time, months 56.5 55.5 ns 55.9 56.9 ns
Disease free
no 6 (6%) 2 (2%) 5 (5%) 3 (3%)
yes 69 (66%) 27 (26%) ns 76 (73%) 20 (19%) ns
Overall survival
died 3 (3%) 1 (1%) 2 (2%) 2 (2%)
alive 72 (69%) 28 (27%) ns 79 (76%) 21 (20%) ns
Abbreviations: BMi, bone marrow involvement; LNi, lymph node involvement;
ns, nonsignificant
Table 5 Correlation of clinical outcome with breast
subtypes
ERBB2+ Triple-negative Luminal
DTC in bone marrow
no 5 (71%) 15 (79%) 61 (78%) ns
yes 2 (29%) 5 (21%) 4 (22%) ns
Disease-free
no 2 (29%) 4 (21%) 2 (3%) p = 0.001
yes 5 (71%) 15 (79%) 76 (97%)
Abbreviations: DTC, disseminated tumor cells; ns, nonsignificant
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ferent disease stages, the presence of DTC in bone mar-
row in the low-risk subgroup (patients who had tumors
no larger than 2 cm and no lymph node involvement,
and who were not undergoing adjuvant therapy) was
associated with a 3.65-fold increase in the risk of breast
cancer mortality and a 2-fold increase in the risk of dis-
tant metastasis during the first 5 years. In this study and
others [24] DTC is described to have independent prog-
nostic value, among other known prognostic factors.
Nonetheless, other authors consider that the long-term
predictive capacity of this factor is not conclusive in
patients with initial-stage disease [8].
The differences in the results of these studies may be
explained by the differing methods and study designs
used, small size of the study groups, heterogeneity of
the patients included, short follow-up periods, and dif-
fering treatment regimens applied. In addition, bias can
occur when heterogeneous pools of patients from sev-
eral institutions are investigated or when results from
patients in early disease stages are combined with those
from patients with known metastatic disease [25-29].
This is not the case of our study, which focused on a
homogeneous group of patients who had no evidence of
disseminated disease at the time of primary surgery,
were receiving adjuvant systemic treatment, and were
evaluated in terms of survival for a maximum of 6 years
of follow-up.
Another aspect is the diversity of techniques used by
different groups for determining bone marrow dissemi-
nation. We used an immunoassay that meets the ISH-
AGE committee’s recommendations for detecting tumor
cells in bone marrow [15] to ensure high reproducibility
of results. To determine the detection capability, we
tested the sensitivity of the method with isolated MCF-7
mononuclear cells, which show high cytokeratin expres-
sion. Based on the results, we did not contemplate the
use of cell enrichment methods with magnetic particles
[30]. Furthermore, we did not consider it appropriate to
perform peripheral blood determinations because they
require a larger sample volume and offer less reproduci-
ble results [31,32]. These issues have been extensively
discussed in the meta-analysis of Weinschenker et al
[33], which includes the results from 9 series published
between 1991 and 2002. The findings are discussed
in light of the heterogeneity of the methods used in a
heterogeneous pool of patients treated with different
regimens.
Lymph node involvement investigated in patients who
underwent SLN biopsy or complete axillary lymph node
dissection yielded 28% of positive results (29/104), which
is within the expected number for patients with early dis-
ease. In addition, the 63% incidence (17/27) of lymph
node microinvasion could be expected, considering that
these patients had undergone ultrasound study and clini-
cal examination, which are highly effective for ruling out
macroscopic nodal involvement. It may be surprising that
none of the biopsies of the internal mammary area were
found to be positive, even taking into account the high
percentage of locations in the inner quadrants and central
area (around 30%).
Simultaneous bone marrow and lymph node involve-
ment was detected in 5 of 104 patients, in 1 case by
micrometastasis. These findings suggest that tumor cell
dissemination to the two sites rarely occurs simulta-
neously in the early stages of the disease, as has been
reported by other authors. In the series of Braun et al
[27], only 1% (2/150) of patients simultaneously pre-
sented micrometastasis via lymphatic and hematogenous
route, and Gerber et al [34] found only 5% of microme-
tastasis in the two specimens. More recently, Langer et
al [35] described similar rates of nodal involvement and
BM micrometastasis, but agreement was 20% between
the two specimens.
According to the recently reported results of the
ACOSOG Z-010 study [36] in a series of 5539 patients,
DTC in bone marrow was a significant predictor of an
i n c r e a s e dr i s ko fd e a t h ,w h e r e a sS L Nm i c r o m e t a s t a s i s
was not a significant prognostic factor in this regard.
However, BM metastasis was detected in 105 of the
3491 patients examined (3%). In our experience, DTC in
bone marrow was also associated with a higher risk of
relapse and death, but differences were not statistically
significant (see Table 4).
As occurred in other studies [17,24], hematogenous
involvement was linked to other parameters of prognos-
tic interest, such as older age (P < 0.05), radiologic pre-
sentation as a nodule (P < 0.05), and location in internal
quadrants or central (P < 0.05).
Lastly, the relationship between the events occurring
during follow-up and the different breast cancer sub-
types of the tumor was examined. Not surprisingly,
patients who experienced a relapse showed a significant
relationship with the HR-negative plus HER2-2-negative
tumors, and with HER-2-positive tumors (P < 0.001),
which are known to be associated with poorer survival
[18-20]. As was shown by our results, this fact does not
seem to be related with a higher incidence of DTC in
these subtypes. Considering that patients were included
in the study before the publication of the studies using
adjuvant trastuzumab, patients with HER-2-positive
tumors included did not receive this adjuvant treatment;
this fact could explain the poorer prognosis of this
subgroup.
Conclusions
To conclude, determination of tumor cells by immuno-
cytochemistry in bone marrow aspirates is a valid
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patients with initial-stage breast carcinoma; this finding
was documented in 22% of patients. Hematogenous
spread, which was seen in 28% of patients as an indepen-
dent feature, does not seem to occur in parallel to lymph
node invasion. The survival study showed a higher fre-
quency of disease-related events in patients presenting
with hematogenous involvement. Nonetheless, the biolo-
gical profile of the tumor showed higher power for iden-
tifying the subgroup of patients with poorer survival.
Establishment of comparable research protocols in
both methodological and analytical aspects, as well as in
selection of patients, is needed to derive conclusions
regarding the value of these complex determinations.
The classic prognostic parameters remain highly impor-
tant and a simpler one, the biological profile, is emer-
ging as an easily assessable descriptor with considerable
clinical implications.
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